IBJNews

Lilly's win in Evista patent case crucial, analyst says

Back to TopCommentsE-mailPrintBookmark and Share

A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major victory for the company, says an analyst who closely follows the pharmaceutical industry.

In Wednesday’s decision, U.S. District Court Judge Sarah Evans Barker ruled that Lilly’s method-of-use patents for Evista are valid through 2014, rejecting all the claims of Israel-based generic drug firm Teva Pharmaceuticals Industries Ltd.

Evista, an osteoporosis drug, generated global sales of $1 billion last year, including $700 million in the United States, and is considered a blockbuster drug.
 
“Lilly’s taken a couple of hits lately, so it would have been bad [to lose the case],” said Les Funtleyder, a health care stock analyst at New York-based Miller Tabak & Co.

Earlier this month, the company said it plans eliminate 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses the revenue from its bestselling drug, Zyprexa.

Indianapolis-based Lilly faces the patent expiration of Zyprexa in November 2011, after which it will lose most of the drug’s $4.7 billion in annual sales to cheaper generic versions. In addition, patents will expire by 2014 on four other major Lilly drugs, including Evista.

Challenges to Lilly’s patents aren’t unusual, but disputes brought by Teva warrant serious consideration, Funtleyder said.

“I don’t think a lot of people thought there was a high probability that [Lilly] would lose, because these cases usually go in favor of the innovator,” he said. “But Teva is one of the smarter generics.”

Teva has sought to market a cheaper generic version of Evista, also known as raloxifene.

The decision wasn’t a total victory for Lilly. Barker said its patents on Evista’s particle size are invalid. Lilly said it is considering whether to appeal that part of the ruling.

The expiration date for the particle-size patents, which involve the size of the molecule used in Evista, had been 2017. If Lilly appeals the judge’s ruling, and it is successful, it could market Evista for an additional three years without a threat from generics.

“Patents provide us a limited amount of time to recoup our investments,” Lilly spokesman Mark Taylor said following the decision. “This is how we reinvest that money back into the research and development of the next generation of pharmaceuticals.”

The stock market had little reaction to the court decision. Lilly shares were down 6 cents late this morning, trading at $32.38 each.

 

ADVERTISEMENT

  • Off of Evista
    I, too, had to stop - just too expensive. Do you understand that the patent expires in March 2014? Hope so!
  • EVISTA
    I have been taking EVISTA since it has been on market in 1993 I think it is a great drug I looking forward to it going generic it is so expensive I can hardly afford it.
  • Evista
    I need Evista but had to go off it because I couldn't afford it
    • Evista
      Hoping the patent will be removed. Paying high price for 30day refills is not good. I have been taking Evista since 1993. Do not want to switch now to another drug.
      • Evista
        I will be happy to go to the pharmacy and have a cheaper co pay for Evista. I have been on this drug since 1993. Lets hope it sticks for the patent removal. I don't want to change in taking another drug.
      • evista generic
        I cannot wait until this drug is generic because it is so expensive.

        Thank you!

      Post a comment to this story

      COMMENTS POLICY
      We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
       
      You are legally responsible for what you post and your anonymity is not guaranteed.
       
      Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
       
      No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
       
      We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
       

      Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

      Sponsored by
      ADVERTISEMENT

      facebook - twitter on Facebook & Twitter

      Follow on TwitterFollow IBJ on Facebook:
      Follow on TwitterFollow IBJ's Tweets on these topics:
       
      Subscribe to IBJ
      1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

      2. Does the $100,000,000,000 include salaries for members of Congress?

      3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

      4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

      5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.

      ADVERTISEMENT